By James McNair
Enquirer staff writer
A Washington, D.C.-based public health group is asking the Federal Trade Commission to suspend the TV advertising of a Forest Park company's product that promises to improve male sexual performance.
The complaint was filed Wednesday by the Center for Science in the Public Interest, a nonprofit group that has challenged the advertised claims of companies such as KFC, Procter & Gamble and Smucker's. It contends that ads for Enzyte, a one-a-day pill made by Berkeley Premium Nutraceuticals, are "clearly deceptive."
Berkeley introduced Enzyte, an unregulated supplement made mostly of herbs and minerals, in 2001. Its TV pitchman, Smiling Bob, is frequently seen on ESPN and other channels.
The center says the ads violate the Federal Trade Commission Act prohibition against false or misleading advertising.
"Enzyte is more successful subtracting from the male wallet than it is adding to the male organ," said David Schardt, senior nutritionist at the center. "It's basically just an expensive placebo."
Berkeley said Wednesday it had not seen the complaint.
But the company defended its flagship product. "Medical professionals have established a correlation between reduced cardiovascular function and reduced erectile function," it said. "The industry experts that Berkeley has engaged to create and analyze its formulas have identified third-party studies and trial to support that ingredients in Enzyte help to improve circulatory function."
E-mail jmcnair@enquirer.com.
BUSINESS HEADLINES
Keep on trucking
TLQ's aggressive work force 'all about communication'
Group critical of tax breaks
New CEO hired as revivalist
CBS fined record $550,000 for Jackson's Super flash
Enzyte ads challenged
Peale: Marge Schott's share of Reds sold
Local business summary
Dobbs speaks downtown against offshoring
'Serious' problems reported in Fannie Mae accounting
Business digest
Manufacturing conference may return to N.Ky.
Business People
Software maker to pay back $225M
Top wholesale baker files for bankruptcy
Court limits malpractice coverage